From: Peri-operative chemotherapy in the management of resectable colorectal cancer pulmonary metastases
Total cohort | Peri-operative chemotherapy | Surgery alone | |
---|---|---|---|
n = 51 | n = 38 | n = 13 | |
Number of patients | 51 | 38 | 13 |
Disease-free interval (range) | 24.1 months | 20.5 months | 27.5 months |
(2.8-64.1) | (11.7-64.1) | (2.8-52.8) | |
Overall survival | |||
Median (95% CI) | 77 months (55–99) | 91 months (61–121) | 67 months (39–96) |
3-year (95% CI) | 86% (72–93) | 85% (68–93) | 87% (56–96) |
5-year (95% CI) | 72% (55–83) | 74% (54–86) | 68% (35–87) |
Relapse free survival | |||
Median (95% CI) | 29 months (18–39) | 30 months (0–68) | 21 months (13–30) |
3-year (95% CI) | 42% (28–55) | 46% (29–61) | 38% (12–56) |
5-year (95% CI) | 31% (18–45) | 33% (22–54) | ≤18%* |
Response to neoadjuvant chemotherapy | |||
n = 39 resections | |||
Complete response | 0 | ||
Tumour reduction | 23 (62%) | ||
Stable disease | 11 (30%) | ||
Disease control | 34 (92%) | ||
Tumour progression | 3 (8%) | ||
No scans available | 2 |